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introduction: Magnetic resonance imaging (MRI) can portray spatial variations in 
tumor heterogeneity, architecture, and its microenvironment in a non-destructive way. 
The objective of this study was to assess the relationship between MRI parameters 
measured on patients in vivo, individual metabolites measured in prostatectomy tissue 
ex vivo, and quantitative histopathology.
Materials and methods: Fresh frozen tissue samples (n = 53 from 15 patients) were 
extracted from transversal prostate slices and linked to in  vivo MR images, allowing 
spatially matching of ex vivo measured metabolites with in vivo MR parameters. Color-
based segmentation of cryosections of each tissue sample was used to identify luminal 
space, stroma, and nuclei.
results: Cancer samples have significantly lower area percentage of lumen and higher 
area percentage of nuclei than non-cancer samples (p ≤ 0.001). Apparent diffusion coef-
ficient is significantly correlated with percentage area of lumen (ρ = 0.6, p < 0.001) and 
percentage area of nuclei (ρ = −0.35, p = 0.01). There is a positive correlation (ρ = 0.31, 
p = 0.053) between citrate and percentage area of lumen. Choline is negatively cor-
related with lumen (ρ = −0.38, p = 0.02) and positively correlated with percentage area 
of nuclei (ρ = 0.38, p = 0.02).
conclusion: Microstructures that are observed by histopathology are linked to MR 
characteristics and metabolite levels observed in prostate cancer.
Keywords: aDc, magnetic resonance imaging, citrate, choline, hr-Mas Mrs, color-based segmentation
inTrODUcTiOn
Magnetic resonance imaging (MRI) plays an important role in the diagnostic work-up of prostate 
cancer patients (1). MRI can portray spatial variations in tumor heterogeneity, architecture, and 
its microenvironment in a non-destructive way. Metabolic and morphologic changes in prostate 
cancer tissue lead to changes in MRI and MR spectroscopy (MRS) parameters. In cancer areas of 
the prostate’s peripheral zone, T2 intensity and apparent diffusion coefficient (ADC) are reduced, 
TaBle 1 | characteristics of patients (N = 15) and tissue samples (n = 53).
Patient characteristics Value, median (range)
Age (years) 63.7 (48.0–69.5)
sPSA (ng/ml) 12.0 (5.9–21.4)






7 (3 + 4, 4 + 3) 12 (8, 4)
8 (3 + 5, 4 + 4) 8 (2, 6)
9 (4 + 5, 5 + 4) 8 (5, 3)
Tumor load (%)a, median (range) 60 (10–90)
sPSA, serum prostate-specific antigen at time of surgery; n = number of patients tissue 
samples.
aPercentage tumor in tumor-containing tissue samples.
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while the choline and creatine-to-citrate ratio is increased com-
pared to non-cancer areas (2, 3). These cancer-related changes 
in MR imaging parameters may be caused by a combination 
of increased cellularity, reduced luminal space, and altered 
metabolism.
Attempts have been made to elucidate the relationship between 
MR visible metabolites and MR imaging parameters. A negative 
correlation between ADC and the metabolite ratio choline plus 
creatine-to-citrate has been demonstrated (4). Due to low spec-
tral resolution in vivo, correlation between MRI parameters and 
individual metabolites (such as choline-containing compounds 
and citrate) has not yet been investigated. Ex vivo high-resolution 
spectroscopy data from magic angle spinning (HR-MAS) MRS 
from prostate cancer can be linked to in vivo MR parameters as 
previously described (5), and individual metabolites can there-
fore be correlated with MRI parameters.
In the prostate, healthy peripheral zone has heterogeneous 
tissue architecture and consists primarily of glandular lumen 
lined with secretory epithelium embedded within a stromal 
matrix (6). Healthy prostate tissue is characterized by high 
levels of citrate since the glandular secretory epithelial cells 
have the ability to produce, accumulate, and secrete citrate (7). 
The water content is low in stroma, but high in luminal space 
resulting in a relatively long T2 and unrestricted water diffusion. 
As a result, healthy peripheral zone shows high signal intensity 
in T2-weighted images and on ADC maps, while T2 intensity 
and ADC are reduced in cancer (8–14). However, it has been 
demonstrated by Bourne et al. that the secretory epithelia within 
healthy peripheral zone represent a compartment of highly 
restricted water diffusion (6) and that healthy peripheral zone in 
general displays two T2 components, one liquid-like component 
with long T2 time originating from the luminal space and one 
component with a short T2 time originating from stromal and 
epithelial tissues (15). Further, significant correlations between 
imaging parameters and histological features, such as luminal 
space, cell density, percentage of nuclei, and cytoplasm, have 
been demonstrated (16–18).
The objective of this study was to assess the relationship 
between MRI parameters (T2 intensity and ADC) measured 
on patients in  vivo, individual metabolites measured in pros-
tatectomy tissue ex vivo and quantitative histopathological 
features (percentage nuclei, stroma, and luminal space). An 
overview of these relationships could give a better insight into 
the origin of the observed MRI and MRS signals and contribute 
to  better understanding of the similarities and differences of 
these parameters.
MaTerials anD MeThODs
Patients and Tissue samples
The Regional Committee for Medical Research Ethics approved 
the study, and patients gave informed written consent to par-
ticipate. Fresh frozen tissue samples [n =  53 from 15 patients, 
median 3 (range 2–6) per patient] were extracted from transversal 
prostate slices and linked to in vivo MR parameters as previously 
described (5, 19). In short, a full transversal, fresh tissue slice 
(2 mm thick) was resected from the middle of the prostate and 
snap-frozen. Tissue samples (3 mm in diameter) were thereafter 
drilled out of the frozen tissue slice, and locations of removed 
samples were documented on a photo. Preoperative MR images 
best corresponding to the level of the resected tissue slice were 
identified, and circular regions of interest were outlined accord-
ing to the location of the removed tissue samples. Patient and 
tissue sample characteristics are listed in Table 1.
Mr imaging
Magnetic resonance imaging was performed as previously 
described (2). In short, patients with biopsy proven prostate 
cancer underwent a preoperative multiparametric MR examina-
tion including T2-weighted imaging (T2WI), diffusion-weighted 
imaging (DWI), MR spectroscopic imaging [MRSI; results previ-
ously reported in Ref. (2, 5) and not shown here], and dynamic 
contrast-enhanced magnetic resonance imaging [DCE-MRI; 
results previously reported in Ref. (2) and not shown here] on 
a 3-T system (Magnetom Trio, Siemens Medical Solutions, 
Erlangen, Germany). Phased array body coil and spine coil ele-
ments were used for signal detection. T2-weighted turbo spin 
echo images were obtained in three orthogonal planes. The 
transversal T2-weighed images (TR/TE 4210  ms/104  ms, FOV 
160 mm × 160 mm, matrix 320 × 256, slice thickness 3 mm, and 
acquisition time 5  min 47  s) were angulated perpendicular to 
the urethra to replicate the angle of slicing for histopathological 
analysis. Diffusion-weighted images [TR/TE 3500  ms/77  ms, 
FOV 340 mm × 168 mm, matrix 170 × 170, slice thickness 4 mm, 
four b-values (50, 300, 600, and 800 s/mm2), and acquisition time 
2  min 59  s] and dynamic contrast-enhanced images (TR/TE 
4 ms/1.34 ms, FOV 280 mm × 227.6 mm, matrix 256 × 230.4, slice 
thickness 2 mm, temporal resolution 12.9 s, and total acquisition 
time 5  min 32  s) were equally angulated. T2-weighted images 
and ADC maps were used to calculate T2 intensities and ADC in 
regions of interest corresponding to tissue resection areas.
hr-Mas Mrs experiment
1H HR-MAS MR spectra of the tissue samples were obtained using 
a 14.1-T spectrometer (Bruker Avance DRX 600, Bruker BioSpin 
FigUre 1 | (a) ADC map with ROIs from cancer (red outline) and non-cancer peripheral zone (green outline) areas corresponding to extracted tissue samples. 
(B) H&E stained slides (4× objective) of cryosections with Gleason 5 + 4 (red) and non-cancer (green) tissue. Red and green outline refer to tissue location in (a). 
(c) Close-up view of corresponding color-based segmentation with setting 2. Negative pixels (blue color) correspond to stroma; positive pixels (yellow and orange 
color) correspond to cytoplasm and nuclei; lumen is calculated as total number of pixels minus positive and negative (white color).
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GmbH, Karlsruhe, Germany) and post-processed as previously 
described (20). Quantification of metabolites was performed by 
LC Model (21), as described by Giskeødegård et al. (20).
histopathology and color-Based 
segmentation
A cryosection was taken from each tissue sample and stained with 
hematoxylin and eosin (H&E). These H&E-stained slides were 
digitized with 4× magnification, and color-based segmentation 
(Positive Pixel Count algorithm in ImageScope v.11, Aperio 
Technologies) was used to identify luminal space, stroma, and 
nuclei, as described by Langer et al. (16). In short, two hue and 
windows settings were used (setting 1: 0.1 for hue, 0.5 for window; 
setting 2: 0.7 for hue, 0.35 for window) and optimized for each 
histologic slide by adjusting the window on a test region such 
that negative pixels in setting 1 represented nuclei, negative pixels 
in setting 2 represented stroma, and positive pixels in setting 2 
represented cytoplasm and nuclei. Lumen was calculated as total 
area minus positive and negative pixels in setting 2 (Figure 1). 
For all the components (lumen, stroma, and nuclei), percentage 
of total area was used in the calculations. One tissue sample (GS 
4 + 4) was excluded from color-based segmentation due to poor 
quality of the H&E slide. The metabolite concentrations from this 
tissue sample were included in the analyses when metabolites 
were correlated with MR parameters.
statistics
The Kolmogorov–Smirnov test was used to test data normality. 
Linear mixed model was used for pairwise comparison of histo-
logical components and different Gleason scores. Linear mixed 
model was also used to evaluate the association between MR 
parameters, metabolites, and histological features. Parameters 
that were not normally distributed were log-transformed before 
being entered in the linear mixed model. To account for multi-
ple samples per patient, patient identification was entered as a 
random effect on the intercept in the model. Spearman’s rank 
correlation (ρ) was calculated between in vivo MR parameters, 
ex vivo metabolite concentrations, and histological features since 
they were not all normally distributed. This measure does not 
take into account multiple samples per patient. Multiple com-
parisons were corrected for with the Benjamini and Hochberg 
false discovery rate. Adjusted p values <0.05 were considered 
significant. All statistical analyses were performed using SPSS 
(IBM SPSS Statistics 22.0), except Benjamini and Hochberg cor-
rections, which were performed in Matlab (MATLAB R2009a, 
The MathWorks Inc., Natick, MA, USA).
resUlTs
An overview of histological components in cancer and non-cancer 
samples is given in Table  2. Cancer samples have significantly 
lower area percentage of lumen and higher area percentage of 
nuclei than non-cancer samples (p ≤ 0.001). Percentage area of 
stroma is not significantly different between cancer and non-
cancer samples (p =  0.3). There are no significant differences 
between histological parameters in tissue samples with different 
Gleason scores except for percentage area of lumen in Gleason 
score 9 samples, which are significantly lower than for Gleason 
scores 6 and 7 (Figure 2).
The in  vivo-measured MR parameters, T2 intensity and 
ADC, are reduced in areas of cancer compared to non-cancer 
(Table 3) (p < 0.001). There is a trend toward reduced ADC and 
T2 intensity with higher Gleason score and a significantly lower 
ADC in Gleason score 9 samples compared to Gleason score 6 
samples (p = 0.02). The ex vivo-measured metabolite concentra-
tions of citrate and choline is reduced and increased, respectively, 
in cancer samples compared to non-cancer samples (Table  3). 
There is a trend toward increased choline and decreased citrate 
with increased Gleason score and significantly lower citrate in 
Gleason score 9 samples compared to Gleason score 6 samples 
(p = 0.01). There are no significant differences in choline between 
samples with different Gleason scores.
TaBle 4 | correlation coefficients between Mr parameters and 
histological features.
lumen (%) nuclei (%) stroma (%) gleason score
ADC (×10−6 mm2/s) 0.60 (<0.001) −0.35 (0.03) −0.01 (0.99) −0.58 (<0.001)
Citrate  
(mmol/kga)
0.31 (0.05) 0.09 (0.71) −0.01 (0.99) −0.46 (0.002)
Choline  
(mmol/kga)
−0.38 (0.01) 0.38 (0.01) −0.19 (0.31) 0.55 (<0.001)
Spermine  
(mmol/kga)
0.18 (0.37) 0.12 (0.67) 0.004 (0.99) −0.31 (0.05)
Creatine  
(mmol/kga)
−0.09 (0.71) 0.07 (0.57) 0.08 (0.71) −0.07 (0.71)
(cho + spm + 
cre)/cit
−0.49 (0.001) 0.07 (0.71) 0.003 (0.99) 0.60 (<0.001)
(cit + spm +  
cre)/cho
0.45 (0.003) −0.22 (0.24) 0.13 (0.55) −0.69 (<0.001)
Gleason score −0.62 (<0.001) 0.40 (0.01) −0.14 (0.51)
Denoted in brackets are the p-values corrected for multiple testing with Benjamini and 
Hochberg false discovery rate approach.
cho, choline; spm, spermine; cre, creatine; cit, citrate.
Bold font indicates a significant correlation (<0.05 after correction from multiple 
comparisons)
aMetabolite concentrations are reported as millimoles per kilogram wet weight.












Non-cancer 1572 ± 95 353 ± 31 1.19 ± 0.1 9.8 ± 1.4 14
Cancer 1146 ± 44 250 ± 11 2.8 ± 0.3 6.6 ± 0.7 39
GS 6 1265 ± 97 281 ± 18 2.0 ± 0.5 9.7 ± 1.4 11
GS 7 1164 ± 70 254 ± 22 3.0 ± 0.5 5.4 ± 1.1 12
GS 8 1180 ± 88 232 ± 21 2.8 ± 0.5 7.1 ± 1.6 8
GS 9 921 ± 60 220 ± 21 3.7 ± 0.8 3.6 ± 0.9 8
Numbers are mean ± SE. Bold font indicates a significant difference from non-cancer 
samples (p < 0.05 after correction for multiple comparisons).
aSum of all choline-containing compounds.
bCholine and citrate concentrations are reported as millimoles per kilogram wet weight. 
T2 intensity, total choline, and citrate levels were not normally distributed and thus were 
log-transformed before being entered into the linear mixed model.
FigUre 2 | Box-plot showing association between gleason score and 
percentage area of lumen.
TaBle 2 | area percentage of histological components.
lumen (%) stroma (%) nuclei (%) no. of samples
Tissue type
Non-cancer 13.8 ± 1.6 54.8 ± 1.9 23.3 ± 1.9 14
Cancer 7.5 ± 0.9 50.7 ± 1.2 30.3 ± 1.0 38
GS 6 10.4 ± 1.5 50.2 ± 1.7 28.5 ± 1.6 11
GS 7 8.2 ± 1.7 47.9 ± 2.1 31.2 ± 2.0 12
GS 8 7.7 ± 1.4 52.0 ± 3.1 31.5 ± 2.4 7
GS 9 2.3 ± 0.4 54.4 ± 3.1 30.5 ± 2.2 8
Numbers are mean ± SE. Bold font indicates a significant difference from non-cancer 
samples (p < 0.05 after correction for multiple comparisons).
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There is an intermediate to strong positive correlation between 
ADC and percentage area of lumen (ρ = 0.6, p < 0.001). There 
is a weaker, but significant, negative correlation between ADC 
and percentage area of nuclei (ρ = −0.35, p =  0.01) (Table  4; 
Figure 3). ADC, percentage area of lumen, and percentage area 
of nuclei are all correlated with Gleason score in the tissue sample 
(ρ = −0.58, p < 0.001; ρ = −0.62, p < 0.001; and ρ = 0.4, p = 0.01, 
respectively) (Table 4). When only non-cancer samples (n = 14) 
are considered, there is still a strong correlation between ADC 
and lumen (ρ = 0.7, p = 0.005), while the correlation between 
ADC and nuclei is no longer significant (ρ = −0.007, p = 0.982). 
In linear mixed model analysis, percentage area of lumen, nuclei, 
and Gleason score are significant covariates of ADC (p < 0.001, 
p = 0.014, and p < 0.001, respectively). Percentage area of stroma is 
not significantly correlated with ADC or Gleason score (Table 4).
There is a positive correlation (ρ = 0.31) between Citrate and 
percentage area of lumen, however after correcting for multiple 
testing, it is only borderline significant at the 0.05 level (p = 0.053). 
With linear mixed model, lumen is a significant covariate of 
citrate (p = 0.005). Choline is negatively correlated with lumen 
(ρ = −0.38, p = 0.02) and positively correlated with percentage 
area of nuclei (ρ = 0.38, p = 0.02). Both citrate and choline are 
significantly correlated with Gleason score (ρ = −0.46, p = 0.002; 
ρ = 0.55, p < 0.001, respectively). When only non-cancer samples 
are considered (n =  14) citrate is not significantly correlated 
with percentage area of lumen (ρ = 0.15, p = 0.65) and choline 
is not significantly correlated with lumen or nuclei (ρ =  0.01, 
p  =  0.95; ρ  =  0.24, p  =  0.41, respectively). The relationship 
between percentage area of lumen, citrate, choline, and Gleason 
score is visualized in Figure  4. Spermine and creatine are not 
significantly correlated with any of the glandular components, 
but the ratios (choline +  spermine + creatine)/citrate and (cit-
rate + spermine + creatine)/choline are significantly correlated 
with percentage area of lumen (ρ = 0.49, p = 0.002; ρ = −0.45, 
p = 0.004, respectively) (Table 4).
DiscUssiOn
In this study, we have explored the relationship between MR 
parameters measured in vivo (ADC and T2 intensity), metabolite 
concentrations (citrate, choline, creatine, and spermine) measured 
ex vivo with HR-MAS MRS, and histological gland components 
(percentage area of lumen, nuclei, and stroma) extracted from 
histopathology with color-based segmentation.
FigUre 3 | scatterplot showing the relationship between aDc and percentage area of lumen (a) and percentage area of nuclei (B), respectively.
FigUre 4 | scatterplot showing the relationship between percentage area of lumen and citrate (a) and choline (B), respectively. *Citrate and choline 
concentrations are reported as millimoles per kilogram wet weight.
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As expected, we find a clear difference in histological features 
between cancer and non-cancer samples. The decrease in per-
centage of luminal space and increase in percentage area of nuclei 
in cancer samples compared to non-cancer samples is in line with 
previous reported findings by several groups (16, 22, 23). The 
percentage area of lumen in healthy prostate tissue has previously 
been reported to be in the range of 20–30% (16, 22), which is 
higher than we observed. Previous studies have performed color-
based segmentation on H&E-stained whole mount sections while 
we used H&E-stained cryosections. H&E staining of cryosections 
can be of lower quality than staining of paraffin-embedded tis-
sue, and this might explain some of the discrepancy. Further, our 
samples were 3 mm in diameter, and luminal space on the edges 
was omitted in the segmentation, which could also result in lower 
values. However, we observed a trend toward decreased percent-
age area of lumen with increased Gleason score, consistent with 
previous findings (16, 23). The literature is inconsistent regarding 
stroma content in cancer versus non-cancer tissue (16, 22, 23); 
however, there was no evidence of differences in percentage area 
of stroma in our data.
We find a significantly increased percentage area of nuclei 
in cancer samples compared to non-cancer samples. In cancer 
samples, we see a weak trend toward increased area of nuclei with 
increased Gleason score; however, there is no significant differ-
ence between different Gleason scores. A trend toward increasing 
cellularity metrics with increasing Gleason pattern is described in 
numerous articles, but most of them lack significant differences 
between Gleason groups (16, 17, 22–24). This has often been 
attributed to the limited range of Gleason scores in the study 
cohorts. However, in our study, we have tissue samples ranging 
from non-cancer to Gleason score 9 with approximately equal 
number of samples in each group and still find no significant 
differences. This might be a result of the nature of the Gleason 
scoring system, where each pattern is based on tissue architecture 
rather than cellularity per se. This finding might also explain the 
lack of significant differences in choline between different Gleason 
6Selnæs et al. MR Parameters and Tissue Microstructure
Frontiers in Oncology | www.frontiersin.org June 2016 | Volume 6 | Article 146
scores, although there is a positive correlation between choline 
and percentage area of nuclei (ρ = 0.38, p = 0.021) in our data.
The basis for the widespread use of MR imaging in prostate 
cancer diagnostics is the reduced T2 intensity and ADC in cancer 
compared to healthy prostate (2, 3, 9), which this study also con-
firms. The observed trend toward decreased ADC and T2 intensity 
with increased Gleason score is also in line with previous findings 
(25, 26). It is likely that observed changes in tissue composition 
in cancer compared to non-cancer areas are responsible for the 
observed changes in MRI parameters. A more detailed investiga-
tion of the correlations between MR parameters and glandular 
components could help us to understand what underlying struc-
tural changes have the strongest effect on the observed changes 
in the MR images. Bourne et  al. highlight that there are three 
diffusion compartments in prostate tissue: ductal lumen with 
close to free diffusion, stromal tissue with intermediate diffusion, 
and epithelium with highly restricted diffusion (6). In our data, 
we see a positive correlation between ADC and percentage area 
of lumen. Since there is also a trend toward decreasing ADC with 
increasing Gleason score, we also tested the correlation between 
ADC and lumen in the non-cancer samples with a strong signifi-
cant correlation also in that cohort. The percentage area of nuclei 
was negatively correlated with ADC; however, there was no cor-
relation between ADC and nuclei when only non-cancer samples 
were investigated. Combined, these results indicate that in low 
resolution clinical DW images, the amount of luminal space is 
the main contributor to the measured ADC value, rather than 
increased cellularity, which is often used as the default explana-
tion for reduced ADC in cancer imaging.
Altered tissue metabolism is an emerging hallmark of cancer 
(27). Although it is likely that metabolites that are stored in the 
luminal space, such as citrate and spermine, will be reduced when 
the lumen is invaded by cancer tissue, the observed change in 
metabolites between cancer and non-cancer tissue could also 
be due to cancer-related changes in metabolism. In our cohort, 
both citrate and luminal space were decreasing with increasing 
Gleason score. A weak correlation between citrate and luminal 
space was observed, but there was not a significant correlation 
when only normal samples were investigated. This could be due 
to the low number of non-cancer samples; however, it could also 
indicate that the correlation between citrate and luminal space 
is an indirect effect of their association with Gleason score. This 
could further indicate that the changes in metabolites, seen in 
cancer on MRSI, are not solely dependent on tissue composi-
tion and that citrate and choline measurements from MRSI give 
complementary information to ADC and T2WI.
In vivo MRSI has lower spectral resolution than ex vivo 
HR-MAS MRS, and metabolite ratios, rather than individual 
metabolites, are therefore often reported for MRSI studies. The 
ratio of choline, polyamines (mainly spermine), and creatine-to-
citrate is often used, since the resonances of choline, polyamines, 
and creatine can be difficult to separate in a reliable way (2). We 
expected to see a better correlation between individual metabo-
lites and glandular features than by using metabolite ratios; 
however, this was not the case. The metabolites citrate and sper-
mine are both stored in the prostatic fluid in the lumen, and it 
would therefore make sense to calculate a metabolite ratio where 
citrate and spermine are added. Kobus et al. (22) focused on the 
metabolite ratio citrate, spermine, and creatine-to-choline and 
found a positive correlation with lumen with correlation coef-
ficient of 0.5. We find a correlation in the same range between 
this ratio and percentage area of lumen (ρ = 45), even though the 
individual metabolites are weaker correlated with lumen.
This study has some limitations. The low number of tissue 
samples hampered subdivision into peripheral zone and transi-
tion zone samples. There are also some inherent difficulties in the 
matching between in vivo MR images and tissue samples resected 
for HR-MAS NMR experiments and histopathology; however, 
the tissue harvesting method used in this study contributes to 
minimize the matching uncertainty (19). Previous studies have 
shown that there is a good correlation between in vivo and ex vivo 
measured metabolite ratios by using the harvesting and matching 
technique used in this study (5).
The acquired T2-weighted MR images did not allow for quan-
titative T2 measurements, and we therefore used T2 intensity, 
rather than T2 relaxation, in our analysis. Since T2 intensity can 
be affected by other factors than pure T2 relaxation, we chose to 
only do brief descriptive statistics of the T2 intensity. Further for 
ADC calculations, we used a monoexponential diffusion model, 
since this is the model which is available for ADC calculation 
in our clinical scanners. The monoexponential diffusion model 
assumes Gaussian diffusion conditions. This could affect the 
correlation between ADC and percentage area lumen, since the 
lumen contains freely diffusing liquid. Bourne et al. suggest that 
the distinct stromal and glandular diffusion compartments are 
the origin of the biexponential diffusion decay seen in vivo (6). 
Therefore, application of a biexponential diffusion model might 
have resulted in a higher correlation of ADC with area of nuclei 
or stroma.
All samples in this study were taken from patients with prostate 
cancer. The non-cancer samples were taken from a transversal 
prostate slice that contained prostate cancer elsewhere, and it 
is not yet fully understood how the metabolism in normal-
appearing tissue is affected by the adjacent cancer (field effect). The 
citrate production in the histopathologically normal-appearing 
areas could already have been altered and therefore preclude the 
expected correlation between citrate and percentage of lumen in 
non-cancer samples.
cOnclUsiOn
This study adds to the literature of associations between alterations 
in tissue composition, metabolism, and observed MR imaging 
parameters. The microstructures that are observed by histopa-
thology are linked to MR characteristics in prostate cancer, and 
ADC appears to mainly reflect luminal space rather than dense 
tumor structures.
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